Afqir S, Ismaili N, Errihani H (2009) Concurrent chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: current status. J Cancer Res Ther 5(1):3–7. https://doi.org/10.4103/0973-1482.48763

Article  PubMed  Google Scholar 

Al-Sarraf M, LeBlanc M, Giri PG et al (1998) Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16(4):1310–1317. https://doi.org/10.1200/jco.1998.16.4.1310

CAS  Article  PubMed  Google Scholar 

Austin PC (2013) The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 32(16):2837–2849. https://doi.org/10.1002/sim.5705

Article  PubMed  Google Scholar 

Chan AT, Leung SF, Ngan RK et al (2005) Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst 97(7):536–539. https://doi.org/10.1093/jnci/dji084

CAS  Article  PubMed  Google Scholar 

Chan ATC, Hui EP, Ngan RKC et al (2018) Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial. J Clin Oncol 15:10. https://doi.org/10.1200/JCO.2018.77.7847

Article  Google Scholar 

Chen QY, Wen YF, Guo L et al (2011) Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial. J Natl Cancer Inst 103(23):1761–1770. https://doi.org/10.1093/jnci/djr432

Article  PubMed  Google Scholar 

Chen L, Hu CS, Chen XZ et al (2012) Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol 13(2):163–171. https://doi.org/10.1016/s1470-2045(11)70320-5

Article  PubMed  Google Scholar 

Chen L, Hu CS, Chen XZ et al (2017) Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer 75:150–158. https://doi.org/10.1016/j.ejca.2017.01.002

CAS  Article  PubMed  Google Scholar 

Chen YP, Tang LL, Yang Q et al (2018) Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res 24(8):1824–1833. https://doi.org/10.1158/1078-0432.CCR-17-2656

CAS  Article  PubMed  Google Scholar 

Chen YP, Chan ATC, Le QT et al (2019) Nasopharyngeal carcinoma. The Lancet 394(10192):64–80. https://doi.org/10.1016/s0140-6736(19)30956-0

Article  Google Scholar 

Chen Y-P, IsmailaChua NMLK et al (2021a) Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline. J Clin Oncol 39(7):840–859. https://doi.org/10.1200/JCO.20.03237

CAS  Article  PubMed  Google Scholar 

Chen YP, Liu X, Zhou Q et al (2021b) Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. The Lancet 398(10297):303–313. https://doi.org/10.1016/s0140-6736(21)01123-5

CAS  Article  Google Scholar 

Goto Y, Kodaira T, Fuwa N et al (2013) Alternating chemoradiotherapy in patients with nasopharyngeal cancer: prognostic factors and proposal for individualization of therapy. J Radiat Res 54(1):98–107. https://doi.org/10.1093/jrr/rrs071

Article  PubMed  Google Scholar 

He Y, Guo T, Wang J et al (2019) Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma? Ann Transl Med 7(5):104. https://doi.org/10.21037/atm.2019.02.15

CAS  Article  PubMed  PubMed Central  Google Scholar 

Hui EP, Ma BB, Leung SF et al (2009) Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 27(2):242–249. https://doi.org/10.1200/JCO.2008.18.1545

CAS  Article  PubMed  Google Scholar 

Kim E, Matsuse M, Saenko V et al (2012) Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in anaplastic thyroid carcinoma cells. Thyroid 22(7):717–724. https://doi.org/10.1089/thy.2011.0380

CAS  Article  PubMed  PubMed Central  Google Scholar 

Kwong KF, Edelman MJ et al (2005) High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg 129(6):1250–1257. https://doi.org/10.1016/j.jtcvs.2004.12.050

Article  PubMed  Google Scholar 

Li WF, Chen NY, Zhang N et al (2019) Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial. Int J Cancer 145(1):295–305. https://doi.org/10.1002/ijc.32099

CAS  Article  PubMed  Google Scholar 

Lin JC, Jan JS, Hsu CY et al (2003) Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 21(4):631–637. https://doi.org/10.1200/JCO.2003.06.158

Article  PubMed  Google Scholar 

National Cancer Institute-Common Toxicity Criteria Adverse Events Versions 4. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010–06 14_QuickReference_8.5x11.pdf.

National Comprehensive Cancer Network (2021) NCCN clinical practice guidelines in oncology: head and neck cancers. Version 2. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed Apr 2021

Ribassin-Majed L, Marguet S, Lee AWM et al (2017) What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 35(5):498–505. https://doi.org/10.1200/JCO.2016.67.4119

Article  PubMed  Google Scholar 

Rusch VW, Giroux DJ, Kraut MJ et al (2007) Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 25(3):313–318. https://doi.org/10.1200/JCO.2006.08.2826

Article  PubMed  Google Scholar 

Song L, Liu H, Ma L et al (2013) Inhibition of autophagy by 3-MA enhances endoplasmic reticulum stress-induced apoptosis in human nasopharyngeal carcinoma cells. Oncol Lett 6(4):1031–1038. https://doi.org/10.3892/ol.2013.1498

CAS  Article  PubMed  PubMed Central  Google Scholar 

Sun X, Su S, Chen C et al (2014) Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncol 110(3):398–403. https://doi.org/10.1016/j.radonc.2013.10.020

Article  PubMed  Google Scholar 

Sun Y, Li WF, Chen NY et al (2016) Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol 17(11):1509–1520. https://doi.org/10.1016/s1470-2045(16)30410-7

CAS  Article  PubMed  Google Scholar 

Tang LQ, Chen QY, Fan W et al (2013) Prospective study of tailoring whole-body dual-modality [18F]Fluorodeoxyglucose positron emission tomography/computed tomography with plasma Epstein-Barr virus DNA for detecting distant metastasis in endemic nasopharyngeal carcinoma at initial staging. J Clin Oncol 31(23):2861–2869. https://doi.org/10.1200/jco.2012.46.0816

CAS  Article  PubMed  Google Scholar 

White AA, Lee DN, Mazzola E et al (2021) Adjuvant therapy following induction therapy and surgery improves survival in N2-positive non-small cell lung cancer. J Surg Oncol 123(2):579–586. https://doi.org/10.1002/jso.26305

Article  PubMed  Google Scholar 

Zhang X, Du L, Zhao F et al (2016) A phase II clinical trial of concurrent helical tomotherapy plus cetuximab followed by adjuvant chemotherapy with cisplatin and docetaxel for locally advanced nasopharyngeal carcinoma. Int J Biol Sci 12(4):446–453. https://doi.org/10.7150/ijbs.12937

CAS  Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Chen L, Hu GQ et al (2019) Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med 381(12):1124–1135. https://doi.org/10.1056/NEJMoa1905287

CAS  Article  PubMed  Google Scholar 

Zou R, Yuan JJ, Li Q et al (2020) The clinical outcomes and toxicities of induction chemotherapy followed by concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Front Oncol 10:619625. https://doi.org/10.3389/fonc.2020.619625

Article  PubMed  Google Scholar